172 related articles for article (PubMed ID: 11959219)
41. Update in immunosuppression.
Huizinga R
Nephrol Nurs J; 2002 Jun; 29(3):261-7. PubMed ID: 12164076
[TBL] [Abstract][Full Text] [Related]
42. Progress in Immunosuppressive Agents for Solid-Organ Transplantation.
Zhang WQ; Vierling JM
Tex Heart Inst J; 2019 Feb; 46(1):69-70. PubMed ID: 30833848
[No Abstract] [Full Text] [Related]
43. Lipids and Cardiovascular Disease: Putting It All Together.
Pownall HJ; Gotto AM
Methodist Debakey Cardiovasc J; 2019; 15(1):5-8. PubMed ID: 31049143
[No Abstract] [Full Text] [Related]
44. Polyclonal antibodies in immunosuppression.
Brennan DC
Transplant Proc; 2001; 33(1-2):1002-4. PubMed ID: 11267164
[No Abstract] [Full Text] [Related]
45. Immunosuppression in the pediatric transplant recipient.
Blondet NM; Healey PJ; Hsu E
Semin Pediatr Surg; 2017 Aug; 26(4):193-198. PubMed ID: 28964473
[TBL] [Abstract][Full Text] [Related]
46. Posttransplantation lymphoproliferative disorders.
Andreone P; Gramenzi A; Lorenzini S; Biselli M; Cursaro C; Pileri S; Bernardi M
Arch Intern Med; 2003 Sep; 163(17):1997-2004. PubMed ID: 14504111
[TBL] [Abstract][Full Text] [Related]
47. Starting well: induction immunosuppression after organ transplantation.
Knechtle SJ; Brennan DC
Transpl Int; 2013 Jul; 26(7):661. PubMed ID: 23751168
[No Abstract] [Full Text] [Related]
48. Pharmacological manipulation of the rejection response.
Hopkins PM
Methods Mol Biol; 2006; 333():375-400. PubMed ID: 16790860
[TBL] [Abstract][Full Text] [Related]
49. Cardiovascular risk reduction in renal transplantation. Strategies for success.
Kiberd BA
Minerva Urol Nefrol; 2002 Jun; 54(2):51-63. PubMed ID: 12070454
[TBL] [Abstract][Full Text] [Related]
50. Current world literature.
Curr Opin Organ Transplant; 2010 Oct; 15(5):657-69. PubMed ID: 20844432
[No Abstract] [Full Text] [Related]
51. Immunosuppression in the era of biological agents.
Grinyó JM; Cruzado JM; Bestard O; Vidal Castiñeira JR; Torras J
Adv Exp Med Biol; 2012; 741():60-72. PubMed ID: 22457103
[TBL] [Abstract][Full Text] [Related]
52. [Mechanisms of action of immunosuppressive drugs in organ transplantation].
Manfro RC; Gonçalves LF; Barros E; Prompt CA
Rev Assoc Med Bras (1992); 1992; 38(2):111-6. PubMed ID: 1307065
[No Abstract] [Full Text] [Related]
53. Allograft rejection and corticosteroids in acute pancreatitis following renal and cardiac transplantation.
Hagopian EJ; Chabot JA; Oluwole SF; Benvenisty AI; Hardy MA
Transplant Proc; 1997; 29(1-2):583. PubMed ID: 9123139
[No Abstract] [Full Text] [Related]
54. Strategies for minimizing immunosuppression in kidney transplantation.
Kirk AD; Mannon RB; Swanson SJ; Hale DA
Transpl Int; 2005 Jan; 18(1):2-14. PubMed ID: 15612977
[TBL] [Abstract][Full Text] [Related]
55. Present state of immunosuppressive therapy in liver transplant recipients.
Wiesner RH; Fung JJ
Liver Transpl; 2011 Nov; 17 Suppl 3():S1-9. PubMed ID: 21850697
[TBL] [Abstract][Full Text] [Related]
56. Transplantation. Save our bacon!
Henry ML
Lancet; 1997 Dec 20-27; 350 Suppl 3():SIII28. PubMed ID: 9465203
[No Abstract] [Full Text] [Related]
57. Engineered CD3 antibodies for immunosuppression.
Renders L; Valerius T
Clin Exp Immunol; 2003 Sep; 133(3):307-9. PubMed ID: 12930354
[No Abstract] [Full Text] [Related]
58. The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies.
Kahan BD
Transplant Proc; 2002 Feb; 34(1):130-3. PubMed ID: 11959221
[No Abstract] [Full Text] [Related]
59. Immunosuppression: practice and trends.
Helderman JH; Bennett WM; Cibrik DM; Kaufman DB; Klein A; Takemoto SK
Am J Transplant; 2003; 3 Suppl 4():41-52. PubMed ID: 12694049
[No Abstract] [Full Text] [Related]
60. Immunological risks of minimization strategies.
Snanoudj R; Tinel C; Legendre C
Transpl Int; 2015 Aug; 28(8):901-10. PubMed ID: 25809144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
